ARMO BioSciences (ARMO) Stock Price, News & Analysis

Company Overview

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. Its lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma. The company is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer. In addition, it is developing AM0001, a monoclonal antibody against programmed cell death protein-1 checkpoint inhibitor; AM0015, a recombinant human interleukin-15; AM0012, a recombinant human Interleukin-12; and AM0003, a monoclonal antibody against leukocyte activating gene-3 protein program. The company was formerly known as Targenics, Inc. and changed its name to ARMO BioSciences, Inc. in December 2012. ARMO BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $49.98 to $49.98
• 50-Day Range: $49.98 to $49.98
• 52-Week Range: $25.10 to $57.19
• Volume: N/A
• Average Volume: 201,363 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARMO Stock Analysis - Frequently Asked Questions

How were ARMO BioSciences' earnings last quarter?

ARMO BioSciences, Inc. (NASDAQ:ARMO) issued its quarterly earnings data on Monday, April, 2nd. The company reported ($9.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $9.17.

When did ARMO BioSciences IPO?

ARMO BioSciences (ARMO) raised $100 million in an initial public offering on Friday, January 26th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Baird was co-manager.

What other stocks do shareholders of ARMO BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ARMO BioSciences investors own include Standex International (SXI), Tesla (TSLA), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), AbbVie (ABBV) and Churchill Downs (CHDN).

Company Calendar

• Last Earnings: 4/02/2018
• Today: 6/20/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ARMO
• CIK: 1693664
• Web: www.armobio.com
• Phone: 650-779-5075
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A